Literature DB >> 22580249

First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.

Tom Mabin1, Marc Sapoval, Vincent Cabane, Joanne Stemmett, Mano Iyer.   

Abstract

AIMS: To evaluate a novel modality utilising ultrasound for renal denervation designed to reduce the duration of the intervention as well as to increase the consistency of the clinical outcome. METHODS AND
RESULTS: Eleven consecutive patients suffering from resistant hypertension as defined by the ESH-ESC guidelines were treated by transcatheter renal denervation using the CE-marked PARADISE™ technology (ReCor Medical, Ronkonkoma, NY, USA). An average of 5.1 ultrasound emissions were delivered in each subject for a total denervation duration of less than four minutes and the treatment was well tolerated by all patients. Both office and home blood pressure measurements showed an immediate, significant and sustained decrease in blood pressure. Three-month results were comparable to published data on radiofrequency renal denervation with an average reduction in office and home blood pressure of -36/-17 mmHg and -22/-12 mmHg, respectively.
CONCLUSIONS: Ultrasound renal denervation appears to be a safe and effective treatment for resistant hypertension and further studies will be performed to confirm these preliminary results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580249     DOI: 10.4244/EIJV8I1A10

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  35 in total

Review 1.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

2.  An IVUS transducer for microbubble therapies.

Authors:  Joseph P Kilroy; Abhay V Patil; Joshua J Rychak; John A Hossack
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2014-03       Impact factor: 2.725

3.  Anticipated expansion of a new approach to treating hypertension without medication by catheter-based renal denervation.

Authors:  Keisuke Okamura; Hidenori Urata
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 4.  Novel and nonpharmacologic approaches to cardio-protection in hypertension.

Authors:  Luca Donazzan; Felix Mahfoud; Dominik Linz; Sebastian Ewen; Christian Ukena; Michael Böhm
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 5.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 6.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

Review 7.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 9.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

Review 10.  Interventional treatment of hypertension: a new paradigm.

Authors:  W Schuyler Jones; Sreekanth Vemulapalli; Manesh R Patel
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.